newsfilter
← Latest News
Business Wire·

Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)

– Tafasitamab is approved in combination with lenalidomide for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), and is currently in Phase 3 trials for multiple indications Incyte